I. Kawaguchi

发表

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan

A. Joshi, Hongbo Yang, H. Saeki, 2020, The Journal of dermatological treatment.

Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment with Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan

T. Atsumi, T. Murata, I. Kawaguchi, 2022, Value in Health Regional Issues.

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

T. Hibi, Mamoru Watanabe, H. J. Kim, 2018, Intestinal research.

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial

H. Ihn, K. Papp, C. Nishigori, 2017, The Journal of dermatology.

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

K. Chayama, D. Mitchell, H. Kumada, 2019, Advances in Therapy.

Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

T. Hibi, Mamoru Watanabe, D. Han, 2018, Intestinal research.

Patient preference for biologic treatments of psoriasis in Japan

Y. Tada, K. Ishii, I. Kawaguchi, 2019, The Journal of dermatology.

Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes

H. Murota, B. Calimlim, Y. Koike, 2021, Journal of medical economics.

The association between osteoporosis and patient outcomes in Japan

M. Dibonaventura, Luis A. Yamamoto, I. Kawaguchi, 2016, Journal of medical economics.

Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib.

Y. Sanchez Gonzalez, I. Kawaguchi, Masayuki Saruta, 2024, Journal of medical economics.